Currently, there are several THRβ agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have demonstrated the potential to reduce liver fat and restore liver function. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.